GSK/Medicago COVID-19 Vaccine Looks Like Also-Ran But Antibody Shows Value Against Omicron
Sotrovimab’s Sustained Efficacy Confirmed
Executive Summary
GSK looks unlikely to be a major player in COVID-19 vaccines, even in boosters, but its partnership with Vir could pay off handsomely.
You may also be interested in...
GSK Poaches New Vaccines R&D Chief From Pfizer
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
Harvest Time? Medicago And GSK Expect Summer Readout For Plant-Based COVID Vaccine
Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.